Alkem Laboratories Limited
Momentum (79/100) does the heavy lifting; financial trend (27/100) is the drag.
Buy zoneAlkem Laboratories Limited earns a Buy from StocksWizard, with a blended score of 62/100. At ₹5,751.5 it trades below our blended DCF and relative-multiples fair value of ₹6,670.86, about 16% upside to that estimate — we read it as undervalued by 16%. On 28.2x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹5,842.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹5,956.45 implies about 4% upside across 20 analysts. It clears 10 of 13 investability checks, with durability 64, valuation 69 and momentum 79 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹5,336.69.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-1.56% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy62Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 17.6%
- Pass: Low debt (D/E < 0.5): 0.14x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 15%
- Fail: Earnings growing: -23%
- Pass: Net margin ≥ 10%: 15.6%
- Pass: Current ratio > 1.5: 2.55
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 7.77
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter62.9%
- Institutions25.1%
- Public & other12.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (15.6%).
- Trading near its 52-week high.
- Financially solid — Altman Z 7.77.
Opportunities
- Revenue growing (15% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Earnings contracting year on year.
About Alkem Laboratories Limited
Alkem Laboratories manufactures and sells pharmaceutical and nutraceutical products across India, the United States, and international markets. Its portfolio includes branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals targeting acute and chronic therapeutic areas such as anti-infective, gastroenterology, pain management, iron deficiency, diabetology, and central nervous system conditions.
Alkem Laboratories Limited — frequently asked questions
Is Alkem Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Alkem Laboratories Limited (ALKEM) a Buy, based on a blended score of 62/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Alkem Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Alkem Laboratories Limited's fair value at about ₹6,670.86, versus a current price of ₹5,751.5 — roughly 16% upside. On that basis the stock looks undervalued by 16%.
Is Alkem Laboratories Limited financially healthy?
Alkem Laboratories Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Alkem Laboratories Limited's share price performed?
Alkem Laboratories Limited is up 6% over three months, and last traded at ₹5,751.5. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.